

# Sara I Pai

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5430833/sara-i-pai-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129  
papers

7,149  
citations

36  
h-index

83  
g-index

140  
ext. papers

8,211  
ext. citations

6.3  
avg, IF

5.49  
L-index

#	Paper	IF	Citations
129	Patient-reported outcomes (PROs) from a phase II trial of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal and/or pulmonary involvement.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 6080-6080	2.2	1
128	Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4781-4793	12.9	5
127	Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. <i>Science Immunology</i> , <b>2021</b> , 6,	28	9
126	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 109, 134-144	4	15
125	Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glands. <i>Cancer Reports</i> , <b>2021</b> , e1491	1.5	2
124	Myeloid Cells Are Enriched in Tonsillar Crypts, Providing Insight into the Viral Tropism of Human Papillomavirus. <i>American Journal of Pathology</i> , <b>2021</b> , 191, 1774-1786	5.8	3
123	A rabbit model to investigate temporomandibular joint osteochondral regeneration.. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , <b>2021</b> ,	2	1
122	Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit <b>2020</b> , 8,		1
121	High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. <i>Methods in Enzymology</i> , <b>2020</b> , 635, 1-20	1.7	20
120	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. <i>Nature Biotechnology</i> , <b>2020</b> , 38, 420-425	44.5	20
119	The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. <i>Cancer Treatment and Research</i> , <b>2020</b> , 180, 173-195	3.5	17
118	Peripheral Circulating CD45RAFOXP3 T Regulatory (T) II Cells Provide a Window into the Activity of Intratumoral T Cells. <i>Trends in Cancer</i> , <b>2020</b> , 6, 3-6	12.5	1
117	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee <b>2020</b> , 8,		6
116	High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. <i>American Journal of Ophthalmology</i> , <b>2020</b> , 220, 128-139	4.9	4
115	New technology on the horizon: Fast analytical screening technique FNA (FAST-FNA) enables rapid, multiplex biomarker analysis in head and neck cancers. <i>Cancer Cytopathology</i> , <b>2020</b> , 128, 782-791	3.9	5
114	PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , <b>2020</b> , 36, 444-450	1.4	5
113	Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 1273-1286	7.4	5

112	Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040) <b>2019</b> , 7, 96		20
111	A phase II study of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal, and/or pulmonary involvement.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2502-2502	2.2	4
110	A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 6082-6082	2.2	5
109	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 429	8.5	4
108	Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications. <i>American Journal of Ophthalmology</i> , <b>2019</b> , 200, 226-241	4.9	10
107	PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. <i>Endocrine Pathology</i> , <b>2018</b> , 29, 59-67	4.2	28
106	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. <i>Oral Oncology</i> , <b>2018</b> , 77, 92-97	4.4	6
105	Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. <i>Cancer</i> , <b>2018</b> , 124, 84-94	6.4	12
104	Functional and genomic analyses reveal therapeutic potential of targeting E-catenin/CBP activity in head and neck cancer. <i>Genome Medicine</i> , <b>2018</b> , 10, 54	14.4	20
103	Oncoviruses <b>2018</b> , 90-106		
102	ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6052-6052	2.2	1
101	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- $\gamma$ and IL-12. <i>Immunity</i> , <b>2018</b> , 49, 1148-1161.e7	32.3	352
100	Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 103, e123-e125	2.7	4
99	Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity. <i>Laryngoscope</i> , <b>2017</b> , 127, 1334-1338	3.6	5
98	Programmed cell death ligand 1 as a biomarker in head and neck cancer. <i>Cancer Cytopathology</i> , <b>2017</b> , 125, 529-533	3.9	1
97	High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 179-188	6.6	14
96	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4 TILs in the Presence of PD-L1 TAMs. <i>Cancer Research</i> , <b>2017</b> , 77, 6365-6374	10.1	57
95	Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. <i>Head and Neck</i> , <b>2017</b> , 39, 2433-2443	4.2	4

94	Checkpoint cluster: biomarkers of response. <i>Emerging Topics in Life Sciences</i> , <b>2017</b> , 1, 501-508	3.5	
93	A retrospective cohort study of PD-L1 expression in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SUPREME-HN).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6040-6040	2.2	3
92	IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6053-6053	2.2	6
91	Intact APM and PD-1:PD-L1 pathway upregulation in HIV-infected head and neck cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6058-6058	2.2	
90	Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes. <i>Cancer Immunology, Immunotherapy</i> , <b>2016</b> , 65, 261-71	7.4	6
89	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 510-7	7.5	18
88	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. <i>Oral Oncology</i> , <b>2016</b> , 61, 152-8	4.4	40
87	Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. <i>Oral Oncology</i> , <b>2015</b> , 51, 751-8	4.4	27
86	In-situ tumor vaccination: Bringing the fight to the tumor. <i>Human Vaccines and Immunotherapeutics</i> , <b>2015</b> , 11, 1901-9	4.4	49
85	Xenograft model for therapeutic drug testing in recurrent respiratory papillomatosis. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , <b>2015</b> , 124, 110-5	2.1	10
84	Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e116389	3.7	17
83	A staged thyroidectomy approach for gastric bypass patients. <i>Laryngoscope</i> , <b>2015</b> , 125, 1028-30	3.6	5
82	The Role of Vaccines for HPV-Related Head and Neck Cancers. <i>Head and Neck Cancer Clinics</i> , <b>2015</b> , 99-110.	4	1
81	The impact of molecular testing on the surgical management of patients with thyroid nodules. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 1862-9	3.1	46
80	PET/CT in the management of thyroid cancers. <i>American Journal of Roentgenology</i> , <b>2014</b> , 202, 1316-29	5.4	43
79	Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2408-15	2.2	111
78	BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2718-26	2.2	449
77	Human papillomavirus status of head and neck cancer as determined in cytologic specimens using the hybrid-capture 2 assay. <i>Oral Oncology</i> , <b>2014</b> , 50, 600-4	4.4	28

76	Epidemiology of head and neck squamous cell cancer among HIV-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2014</b> , 65, 603-10	3.1	45
75	HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V. <i>Acta Oncologica</i> , <b>2014</b> , 53, 662-8	3.2	22
74	Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 644-57	12.9	41
73	A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6011-6011	2.2	54
72	A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS3119-TPS3119	2.2	
71	Expression of tumor biomarkers in HIV-infected patients with head and neck cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6086-6086	2.2	
70	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1493-501	27.4	605
69	Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. <i>Cancer</i> , <b>2013</b> , 119, 3462-71	6.4	67
68	Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. <i>Cancer Research</i> , <b>2013</b> , 73, 1733-41	10.1	564
67	Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. <i>Cancer Immunology, Immunotherapy</i> , <b>2013</b> , 62, 171-82	7.4	54
66	The relationship between chronic lymphocytic thyroiditis and central neck lymph node metastasis in North American patients with papillary thyroid carcinoma. <i>Surgery</i> , <b>2013</b> , 154, 1272-80; discussion 1280-2	3.6	34
65	Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas. <i>Oral Oncology</i> , <b>2013</b> , 49, 244-8	4.4	39
64	Oncopolicy in high-income countries can make a difference in HPV-related Head and Neck Cancer. <i>Journal of Cancer Policy</i> , <b>2013</b> , 1, e49-e51	1	1
63	Highly prevalent TERT promoter mutations in aggressive thyroid cancers. <i>Endocrine-Related Cancer</i> , <b>2013</b> , 20, 603-10	5.7	403
62	Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , <b>2013</b> , 2, e24065	7.2	12
61	Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck cancer restricted to the sinonasal tract. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 836-44	6.7	122
60	Human papillomavirus-related carcinomas of the sinonasal tract. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 185-92	6.7	203
59	Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, CRA6031-CRA6031	2.2	3

58	Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, CRA6031-CRA6031	2.2	2
57	Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 1980-7	3.1	11
56	Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status. <i>Cancer Cytopathology</i> , <b>2012</b> , 120, 18-25	3.9	50
55	Incidence of malignancy in thyroid nodules determined to be follicular lesions of undetermined significance on fine-needle aspiration. <i>World Journal of Surgery</i> , <b>2012</b> , 36, 69-74	3.3	35
54	The Superior Laryngeal Nerve <b>2012</b> , 129-135		
53	Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers. <i>Otolaryngologic Clinics of North America</i> , <b>2012</b> , 45, 807-22	2	36
52	Determining the extent of lateral neck dissection necessary to establish regional disease control and avoid reoperation after previous total thyroidectomy and radioactive iodine for papillary thyroid cancer. <i>Head and Neck</i> , <b>2012</b> , 34, 1418-21	4.2	22
51	Hyperfractionated radiotherapy with concurrent cisplatin/5-Fluorouracil for locoregional advanced head and neck cancer: analysis of 105 consecutive patients. <i>International Journal of Otolaryngology</i> , <b>2012</b> , 2012, 754191	1.4	4
50	HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2012</b> , 36, 142-8	6.7	69
49	PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5506-5506	2.2	1
48	Promoter methylation of leukemia inhibitory factor receptor gene in colorectal carcinoma. <i>International Journal of Oncology</i> , <b>2011</b> , 39, 337-44	4.4	13
47	Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. <i>Gene Therapy</i> , <b>2011</b> , 18, 304-12	4	34
46	Tumor size and presence of calcifications on ultrasonography are pre-operative predictors of lymph node metastases in patients with papillary thyroid cancer. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 104, 613-6	2.8	20
45	Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , <b>2011</b> , 33, 1727-34	4.2	25
44	Profile of patients with completion thyroidectomy and assessment of their suitability for outpatient surgery. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2011</b> , 145, 727-31	5.5	5
43	Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 207-17	3.2	38
42	Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1896-905	8.7	53
41	Differential expression of epidermal growth factor receptor in juvenile and adult-onset recurrent respiratory papillomatosis. <i>Histopathology</i> , <b>2010</b> , 57, 768-70	7.3	2

40	Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA. <i>Gene Therapy</i> , <b>2010</b> , 17, 531-40	4	8
39	Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. <i>Cancer Research</i> , <b>2010</b> , 70, 3062-70	10.1	18
38	Reoperation for recurrent/persistent well-differentiated thyroid cancer. <i>Otolaryngologic Clinics of North America</i> , <b>2010</b> , 43, 353-63, ix	2	27
37	Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. <i>Laryngoscope</i> , <b>2010</b> , 120, 504-10	3.6	13
36	Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors. <i>Journal of Biomedical Science</i> , <b>2010</b> , 17, 61	13.3	5
35	Activation of Akt as a mechanism for tumor immune evasion. <i>Molecular Therapy</i> , <b>2009</b> , 17, 439-47	11.7	69
34	Combination of viral oncolysis and tumor-specific immunity to control established tumors. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4581-8	12.9	17
33	Central compartment lymph node dissection. <i>Operative Techniques in Otolaryngology - Head and Neck Surgery</i> , <b>2009</b> , 20, 39-43	0.4	6
32	Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. <i>Laryngoscope</i> , <b>2009</b> , 119, 1542-9	3.6	106
31	Femtosecond laser treatment enhances DNA transfection efficiency in vivo. <i>Journal of Biomedical Science</i> , <b>2009</b> , 16, 36	13.3	22
30	Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. <i>Vaccine</i> , <b>2009</b> , 27, 5450-9	4.1	99
29	Selective versus comprehensive neck dissection after chemoradiation for advanced oropharyngeal squamous cell carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2009</b> , 141, 737-42	5.5	22
28	Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2009</b> , 4, 49-70	34	276
27	The molecular genetics of laryngeal cancer. <i>Otolaryngologic Clinics of North America</i> , <b>2008</b> , 41, 657-72, v	2	25
26	Aggressive recurrent respiratory papillomatosis in a neonate. <i>International Journal of Pediatric Otorhinolaryngology</i> , <b>2008</b> , 72, 917-20	1.7	12
25	Central compartment neck dissection for thyroid cancer. Technical considerations. <i>Orl</i> , <b>2008</b> , 70, 292-7	2	26
24	Immunotherapy for head and neck cancer. <i>Journal of Biomedical Science</i> , <b>2008</b> , 15, 275-89	13.3	15
23	Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. <i>Head and Neck</i> , <b>2008</b> , 30, 898-903	4.2	289

22	Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. <i>Cancer Research</i> , <b>2007</b> , 67, 802-11	10.1	102
21	A retropharyngeal pseudoabscess in a patient with paroxysmal nocturnal hemoglobinuria. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2007</b> , 137, 684-6	5.5	
20	Concurrent sporadic parathyroid adenoma and carcinoma. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , <b>2006</b> , 27, 346-8	2.8	7
19	Prospects of RNA interference therapy for cancer. <i>Gene Therapy</i> , <b>2006</b> , 13, 464-77	4	279
18	The Diagnostic Accuracy of Computed Tomography in Pediatric Chronic Rhinosinusitis. <i>Pediatrics</i> , <b>2005</b> , 116, 551-552	7.4	1
17	Laryngeal muscle surface receptors identified using random phage library. <i>Laryngoscope</i> , <b>2005</b> , 115, 1930-7	4	4
16	A DNA Vaccine Co-Expressing Antigen and an Anti-Apoptotic Molecule Further Enhances the Antigen-Specific CD8+ T-Cell Immune Response. <i>Journal of Biomedical Science</i> , <b>2004</b> , 11, 493-499	13.3	2
15	Comparison of HPV DNA vaccines employing intracellular targeting strategies. <i>Gene Therapy</i> , <b>2004</b> , 11, 1011-8	4	95
14	A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response. <i>Journal of Biomedical Science</i> , <b>2004</b> , 11, 493-9	13.3	25
13	Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. <i>Vaccine</i> , <b>2003</b> , 21, 4036-42	4.1	145
12	Leiomyosarcoma of the auricle. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2003</b> , 128, 442-4	5.5	3
11	Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. <i>Journal of Biomedical Science</i> , <b>2002</b> , 9, 675-687	13.3	23
10	Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. <i>Journal of Biomedical Science</i> , <b>2002</b> , 9, 675-87	13.3	8
9	Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 1203-9	12.9	99
8	B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. <i>Journal of Experimental Medicine</i> , <b>2001</b> , 193, 839-46	16.6	716
7	Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. <i>Gene Therapy</i> , <b>2000</b> , 7, 726-33	4	97
6	Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. <i>Human Gene Therapy</i> , <b>1999</b> , 10, 2727-40	4.8	191
5	Absence of TSG101 transcript abnormalities in human cancers. <i>Oncogene</i> , <b>1998</b> , 16, 2815-8	9.2	11



4	Assignment of two human autoantigen genes-isoleucyl-tRNA synthetase locates to 9q21 and lysyl-tRNA synthetase locates to 16q23-q24. <i>Genomics</i> , <b>1996</b> , 36, 210-3	4.3	6
3	Vasopressin gene related products are markers of human breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>1995</b> , 34, 229-35	4.4	30
2	Localization of two human autoantigen genes by PCR screening and in situ hybridization--glycyl-tRNA synthetase locates to 7p15 and alanyl-tRNA synthetase locates to 16q22. <i>Genomics</i> , <b>1995</b> , 30, 131-2	4.3	3
1	Products of vasopressin gene expression in small-cell carcinoma of the lung. <i>British Journal of Cancer</i> , <b>1994</b> , 69, 260-3	8.7	22